Mouse model for sepsis
脓毒症小鼠模型
基本信息
- 批准号:7191582
- 负责人:
- 金额:$ 39.07万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-06-01 至 2010-02-28
- 项目状态:已结题
- 来源:
- 关键词:AffinityAgonistAlveolar MacrophagesAmmonium SulfateAnimal ModelAnimalsBacteriaBacterial ToxinsBiologicalBiological AssayBloodBone MarrowCattleCaviaCell Adhesion MoleculesCell LineCellsChargeChickensCommunicable DiseasesComplexCultured CellsDNADataEndothelial CellsEnzyme-Linked Immunosorbent AssayEquus caballusFamily suidaeFlagellinFutureGoalsGram-Positive BacteriaHamstersHandHeatingHigh Pressure Liquid ChromatographyHumanHydrophobicityIRAK3 geneImmune responseIn VitroInterleukin-6LeadLectinLipopolysaccharidesLipoproteinsLiteratureLizardsLungMAPK14 geneMass Spectrum AnalysisMediatingMolecularMusOryctolagus cuniculusPan GenusPan troglodytesPapioPatternPeptidoglycanPeripheral Blood Mononuclear CellPeritonealPeritoneal MacrophagesPhosphotransferasesPopulationProductionProteinsRattusResearch PersonnelResistanceRodentSTAT3 geneSamplingSepsisSerumSignal TransductionSourceStimulusSus scrofaSystemTLR2 geneTNF geneTechniquesTechnologyTestingTimeTissuesToll-like receptorsToxinUmbilical veinWorkbasecell typecytokinedesignfetalhuman IRAK1 proteininterestkillingsmacrophagemicrobialmonocytemouse modelpathogenperipheral bloodprogramsprotein purificationresearch studyresistance mechanismresponsesizetwo-dimensional
项目摘要
DESCRIPTION (provided by applicant):
Mice are one of the most commonly utilized species for the initial study of many infectious diseases, including the study of the host response to bacteria. However, mice are 100 to 100,000- fold more resistant than humans in most biological responses to the effects of bacterial lipopolysaccharide (LPS), and to many other microbial toxins. In the literature, and in our hands, macrophages from the two species are generally similar in their sensitivity to LPS, regardless of source. Our preliminary data indicate that there is a soluble substance in the serum of mice that strongly suppresses the production of IL-6 and TNF from mouse and human macrophages that are stimulated with many pathogen associated molecular pattern molecules (PAMPs). These data raise the possibility that the reason that mice are resistant to LPS and other bacterial toxins is the presence of this factor in their blood. The overall goal of the proposed work is to understand the mechanism(s) by which mice are resistant to LPS. Our first specific aim is to systematically study the sensitivity of macrophages and endothelial cells from different tissue compartments from mice and humans (where possible), as well as in cell lines, in the presence of serum from LPS-resistant animals (eg rodent, baboon) and LPS-sensitive animals (eg human, fetal calf). Our second specific aim is to purify the material from mouse serum that inhibits the production of TNF from mouse macrophages. Our third specific aim is to study the cellular level of signaling that is inhibited. The project has broad significance because most experiments using mouse cells are currently performed using media supplemented with fetal calf serum rather than mouse serum, because the proposed work will further our understanding of sepsis caused by bacterial pathogens, and because the work could eventually lead to better animal models for the study of sepsis.
描述(由申请人提供):
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
H Shaw Warren其他文献
H Shaw Warren的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('H Shaw Warren', 18)}}的其他基金
PROTEOMIC CHARACTERIZATION OF CEREBROSPINAL FLUID BY HIGH RESOLUTION LC-MS/MS
通过高分辨率 LC-MS/MS 进行脑脊液蛋白质组学表征
- 批准号:
8365462 - 财政年份:2011
- 资助金额:
$ 39.07万 - 项目类别:
PROTEOMIC CHARACTERIZATION OF CEREBROSPINAL FLUID BY HIGH RESOLUTION LC-MS/MS
通过高分辨率 LC-MS/MS 进行脑脊液蛋白质组学表征
- 批准号:
8170699 - 财政年份:2010
- 资助金额:
$ 39.07万 - 项目类别:
PROTEOMIC CHARACTERIZATION OF CEREBROSPINAL FLUID BY HIGH RESOLUTION LC-MS/MS
通过高分辨率 LC-MS/MS 进行脑脊液蛋白质组学表征
- 批准号:
7957005 - 财政年份:2009
- 资助金额:
$ 39.07万 - 项目类别:
PROTEOMIC CHARACTERIZATION OF CEREBROSPINAL FLUID BY HIGH RESOLUTION LC-MS/MS
通过高分辨率 LC-MS/MS 进行脑脊液蛋白质组学表征
- 批准号:
7721392 - 财政年份:2008
- 资助金额:
$ 39.07万 - 项目类别:
PROTEOMIC CHARACTERIZATION OF CEREBROSPINAL FLUID BY HIGH RESOLUTION LC-MS/MS
通过高分辨率 LC-MS/MS 进行脑脊液蛋白质组学表征
- 批准号:
7602869 - 财政年份:2007
- 资助金额:
$ 39.07万 - 项目类别:
PROTEOMIC CHARACTERIZATION OF CEREBROSPINAL FLUID BY HIGH RESOLUTION LC-MS/MS
通过高分辨率 LC-MS/MS 进行脑脊液蛋白质组学表征
- 批准号:
7359109 - 财政年份:2006
- 资助金额:
$ 39.07万 - 项目类别:
PROTEOMIC CHARACTERIZATION OF CEREBROSPINAL FLUID BY HIGH RESOLUTION LC-MS/MS
通过高分辨率 LC-MS/MS 进行脑脊液蛋白质组学表征
- 批准号:
7183184 - 财政年份:2005
- 资助金额:
$ 39.07万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 39.07万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 39.07万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 39.07万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 39.07万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 39.07万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 39.07万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 39.07万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 39.07万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 39.07万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 39.07万 - 项目类别:














{{item.name}}会员




